Evidence map›Paper›PMID 23739685›Full record

Trial reportThe American journal of sports medicine2013

Changes in circulating biomarkers of muscle atrophy, inflammation, and cartilage turnover in patients undergoing anterior cruciate ligament reconstruction and rehabilitation.

Christopher L Mendias, Evan B Lynch, Max E Davis, Elizabeth R Sibilsky Enselman, Julie A Harning, Paul D Dewolf, Tarek A Makki, Asheesh Bedi

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in The American journal of sports medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02420353 (Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02420353 phase2completednot on this mapstarted 2015, after this paper: background citation

Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears

TypeinterventionalSponsorUniversity of MichiganRan2015 to 2018Enrolled20ConditionsRupture of Anterior Cruciate LigamentArmsSomatropin, Placebo
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Muscle atrophy after ACL reconstruction involves molecular mechanisms beyond unloading.Journal of applied physiology (Bethesda, Md. : 1985) · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Muscle-specific ERRγ activation mitigates muscle atrophy after ACL injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  17. Neurophysiology of ACL Injury.Orthopedic reviews · 2025
    Article
  18. Article
  19. Distinct patterns of cytokines, chemokines, and growth factors in synovial fluid after ACL injury in comparison to osteoarthritis.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Christopher L MendiasDepartment of Orthopaedic Surgery, University of Michigan Medical School, 109 Zina Pitcher Place, BSRB 2017, Ann Arbor, MI 48109-2200, USA. cmendias@umich.edu
Evan B Lynch
Max E Davis
Elizabeth R Sibilsky Enselman
Julie A Harning
Paul D Dewolf
Tarek A Makki
Asheesh Bedi
University of Michigan–Ann Arbor · US

Funding

Faculty Recruitment to Musculoskeletal Research ConsortiumP30AR058920 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GOLDSTEIN, STEVEN A · 2009 to 2010
$780k
NIAMS NIH HHS P30 AR058920
6 · The paper itself

Abstract

backgroundAfter anterior cruciate ligament (ACL) reconstruction, there is significant atrophy of the quadriceps muscles that can limit full recovery and place athletes at risk for recurrent injuries with return to play. The cause of this muscle atrophy is not fully understood. HYPOTHESIS: Circulating levels of proatrophy, proinflammatory, and cartilage turnover cytokines and biomarkers would increase after ACL reconstruction. STUDY

designDescriptive laboratory study.

methodsPatients (N = 18; mean age, 28 ± 2.4 years) underwent surgical reconstruction of the ACL after a noncontact athletic injury. Circulating levels of biomarkers were measured along with Short Form-12, International Knee Documentation Committee, and objective knee strength measures preoperatively and at 6 postoperative visits. Differences were tested using repeated-measures 1-way analysis of variance.

resultsMyostatin, TGF-β, and C-reactive protein levels were significantly increased in the early postoperative period and returned to baseline. Cartilage oligomeric matrix protein levels decreased immediately after surgery and then returned to baseline. CCL2, CCL3, CCL4, CCL5, EGF, FGF-2, IGF-1, IL-10, IL-1α, IL-1β, IL-1ra, IL-6, myoglobin, and TNF-α were not different over the course of the study.

conclusionAn increase in potent atrophy-inducing cytokines and corresponding changes in knee strength and functional scores were observed after ACL reconstruction. CLINICAL RELEVANCE: Although further studies are necessary, the therapeutic inhibition of myostatin may help prevent the muscle atrophy that occurs after ACL reconstruction and provide an accelerated return of patients to sport.

Indexed as

Anterior Cruciate Ligament InjuriesChondrogenesisPostoperative ComplicationsAdolescentAdultAnterior Cruciate Ligament ReconstructionBiomarkersCartilage Oligomeric Matrix ProteinC-Reactive ProteinCytokinesExtracellular Matrix ProteinsFemaleFollow-Up StudiesGlycoproteinsHumansInflammationBiomarkersCartilage Oligomeric Matrix ProteinC-Reactive ProteinCytokinesExtracellular Matrix ProteinsGlycoproteinsInsulin-Like Growth Factor IMatrilin ProteinsMSTN protein, humanMyostatinTransforming Growth Factor betaTSP5 protein, humanACL reconstructioncartilage oligomeric matrix proteinC-reactive proteinmuscle atrophymyostatintransforming growth factor-β

Identifiers

PMID23739685
PMCPMC4086614
OpenAlexW2115525040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.